Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis
- 31 July 2010
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 177 (1), 187-196
- https://doi.org/10.2353/ajpath.2010.090763
Abstract
No abstract availableKeywords
Funding Information
- Fondation pour la Recherche Médicale
This publication has 39 references indexed in Scilit:
- CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injuryMicrovascular Research, 2009
- The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion‐induced cardiomyopathyThe FASEB Journal, 2009
- Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Δ9-tetrahydrocannabinolJournal of Leukocyte Biology, 2008
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1JNCI Journal of the National Cancer Institute, 2008
- Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic RatsJournal of Pharmacology and Experimental Therapeutics, 2007
- Endothelial CB1-receptors limit infarct size through NO formation in rat isolated heartsLife Sciences, 2007
- CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injuryThe FASEB Journal, 2007
- Cannabinoid Receptors CB1 and CB2: A Characterization of Expression and Adenylate Cyclase Modulation within the Immune SystemToxicology and Applied Pharmacology, 1997